Grufity logoGrufity logo
StocksFundsSearch Filings

PTC Therapeutics Inc Stock Research

PTCT

41.97USD+0.81(+1.97%)Market Closed

Market Summary

USD41.97+0.81
Market Closed
1.97%

PTCT Alerts

PTCT Stock Price

PTCT RSI Chart

PTCT Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-5.33

Price/Sales (Trailing)

3.95

EV/EBITDA

-6.7

Price/Free Cashflow

-9.47

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-84.07%

Return on Equity

161.06%

Return on Assets

-32.78%

Free Cashflow Yield

-10.56%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

770.4M

Revenue Y/Y

48.17%

Revenue Q/Q

31.64%

PTCT Earnings

Earnings (TTM)

-571.3M

Earnings Y/Y

-9.65%

Earnings Q/Q

18.68%

Price Action

52 Week Range

25.0159.84
(Low)(High)

Last 7 days

-29.5%

Last 30 days

-25.3%

Last 90 days

-9.0%

Trailing 12 Months

35.6%

PTCT Financial Health

Current Ratio

1.71

PTCT Investor Care

Shares Dilution (1Y)

3.93%

Diluted EPS (TTM)

-8.39

Peers (Alternatives to PTC Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
311.1B
1.6B
-10.47% 70.40%
-162.26
199.76
77.54% 1.62%
285.4B
56.7B
-9.71% -7.25%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-9.13% 5.17%
20.2
7.2
-25.07% -47.28%
83.8B
9.2B
-4.53% 18.84%
25.7
9.1
15.86% 32.99%
23.2B
1.0B
-6.40% 45.93%
-21.75
22.33
22.88% -19.27%
11.6B
975.7M
1.67% 67.21%
-10.42
11.92
27.41% -212.78%
9.6B
2.0B
-10.84% -12.99%
13.17
4.84
12.05% 52.86%
MID-CAP
5.1B
-
-10.25% 307.66%
-16.27
2.5K
- -27.52%
3.4B
204.6M
10.50% 0.21%
-5.87
16.66
-7.52% 10.65%
3.4B
363.3M
10.85% -0.47%
-4.8
9.35
3.39% -55.81%
2.2B
18.9M
-16.27% -6.81%
-2.93
114.18
- -16.17%
SMALL-CAP
3.6B
-
1.50% -9.34%
-8.36
38.06
34.30% -67.22%
1.2B
256.5M
-27.45% 57.57%
12.31
4.77
66.85% 120.61%
288.8M
165.3M
-32.22% 33.43%
-3.16
1.75
130.70% 57.97%
37.4M
-
1.03% 2894.60%
-0.74
19.11
- -29.84%

Financials for PTC Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue10.3%770,447,000698,801,000696,617,000618,233,000569,383,000
Operating Expenses9.0%1,248,952,0001,146,210,0001,028,418,000974,923,000932,204,000
  S&GA Expenses4.2%339,642,000325,998,000319,829,000308,963,000297,949,000
  R&D Expenses8.4%706,543,000651,496,000612,647,000578,030,000546,249,000
EBITDA-6.1%-440,188,000-414,942,000-439,120,000-424,644,000-
EBITDA Margin-5.8%-0.63-0.60-0.71-0.75-
Earnings Before Taxes-2.2%-600,586,000-587,487,000-536,402,000-542,854,000-512,041,000
EBT Margin-9.2%-0.84-0.77-0.88-0.90-
Interest Expenses37.0%25,289,00018,463,00012,678,00012,679,00010,536,000
Net Income-2.2%-571,250,000-559,017,000-531,393,000-555,702,000-521,985,000
Net Income Margin-4.9%-0.80-0.76-0.90-0.92-
Free Cahsflow-33.3%-388,670,000-291,651,000-305,258,000-280,435,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-5.7%1,6091,7061,5761,8041,800
  Current Assets-11.6%613694517695774
    Cash Equivalents-40.1%167280104158152
  Inventory22.2%27.0022.0015.0015.0015.00
  Net PPE9.5%79.0073.0067.0065.0059.00
  Goodwill0.0%82.0082.0082.0082.0082.00
Liabilities0.7%2,0662,0531,8031,9861,890
  Current Liabilities8.7%442406420567477
    LT Debt, Current0.1%150150---
    LT Debt, Non Current0.1%572572283282282
Shareholder's Equity-31.8%-457-347-90.58--
  Retained Earnings-5.2%-2,795-2,656-2,486-2,376-2,224
  Additional Paid-In Capital1.5%2,3402,3052,2232,1842,153
Shares Outstanding1.2%74.0073.0072.0072.0071.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations19.0%-288-356-259-272-248
  Share Based Compensation2.0%113110109106104
Cashflow From Investing-26.9%212290326254238
Cashflow From Financing1.7%171168-13012.0013.00

Risks for PTCT

What is the probability of a big loss on PTCT?

97.7%


Probability that PTC Therapeutics stock will be more than 20% underwater in next one year

75.8%


Probability that PTC Therapeutics stock will be more than 30% underwater in next one year.

17.7%


Probability that PTC Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PTCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if PTC Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for PTCT

Cumulative Returns on PTCT

26.0%


7-Year Cumulative Returns

4.0%


5-Year Cumulative Returns

-6.7%


3-Year Cumulative Returns

What are the long-term rolling returns for PTCT?

FIve years rolling returns for PTC Therapeutics.

Annualized Returns

Which funds bought or sold PTCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-10.67
76,430
648,369
-%
2023-05-23
Brookfield Corp /ON/
reduced
-4.95
864,244
5,053,740
0.02%
2023-05-22
AMERIPRISE FINANCIAL INC
added
56.04
1,943,300
3,926,300
-%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-20.17
30,212
2,334,420
-%
2023-05-18
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
reduced
-35.42
-988,680
4,504,920
1.26%
2023-05-18
JPMORGAN CHASE & CO
added
0.78
9,174,000
42,068,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-7.55
506,000
3,424,000
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-11.67
-197,798
404,602
-%
2023-05-16
JANE STREET GROUP, LLC
new
-
1,071,660
1,071,660
-%
2023-05-16
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
reduced
-24.29
-180,951
4,430,710
0.10%

1–10 of 39

Latest Funds Activity

Are funds buying PTCT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own PTCT
No. of Funds

PTC Therapeutics News

InvestorPlace
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs.
InvestorPlace,
3 hours ago
InvestorPlace
InvestorPlace
InvestorPlace
Investor's Business Daily

Schedule 13G FIlings of PTC Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
rtw investments, lp
7.7%
5,615,387
SC 13G/A
Feb 09, 2023
janus henderson group plc
2.8%
2,027,142
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.21%
7,339,520
SC 13G/A
Feb 06, 2023
wellington management group llp
10.34%
7,430,907
SC 13G/A
Feb 01, 2023
franklin resources inc
4.8%
3,489,687
SC 13G/A
Jan 24, 2023
blackrock inc.
9.2%
6,640,854
SC 13G/A
Jul 11, 2022
vanguard group inc
10.07%
7,183,692
SC 13G/A
Feb 14, 2022
rtw investments, lp
7.5%
5,293,966
SC 13G/A
Feb 11, 2022
hartford mutual funds inc/ct
0%
0
SC 13G

PTCT Fair Value

Show Fair-Value

Recent SEC filings of PTC Therapeutics

View All Filings
Date Filed Form Type Document
May 24, 2023
4
Insider Trading
May 23, 2023
144
Notice of Insider Sale Intent
May 23, 2023
4
Insider Trading
May 23, 2023
8-K
Current Report
May 22, 2023
144
Notice of Insider Sale Intent
May 22, 2023
144
Notice of Insider Sale Intent
May 19, 2023
144
Notice of Insider Sale Intent
May 19, 2023
4
Insider Trading
May 18, 2023
144
Notice of Insider Sale Intent
May 17, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for PTCT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-23
Reeve Emma
acquired
88,520
33.3786
2,652
-
2023-05-23
Reeve Emma
sold
-157,885
59.5342
-2,652
-
2023-05-22
Pauwels Eric
sold
-118,791
59.0122
-2,013
chief business officer
2023-05-22
Reeve Emma
acquired
237,484
33.3733
7,116
-
2023-05-22
Reeve Emma
sold
-423,630
59.5321
-7,116
-
2023-05-19
Pauwels Eric
sold
-377,491
58.9553
-6,403
chief business officer
2023-05-18
Pauwels Eric
sold
-46,266
58.7143
-788
chief business officer
2023-05-17
Pauwels Eric
sold
-470,822
58.5017
-8,048
chief business officer
2023-05-11
Jacobson Allan Steven
sold
-1,266,930
55.0839
-23,000
-
2023-05-11
Jacobson Allan Steven
acquired
249,550
10.85
23,000
-

1–10 of 50

Stuart W. Peltz
1180
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Income Statement

2023-03-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:  
Revenue$ 220,382$ 148,735
Operating expenses:  
Cost of product sales, excluding amortization of acquired intangible assets14,14410,135
Amortization of intangible assets39,41523,473
Research and development195,124140,078
Selling, general and administrative86,91473,271
Change in the fair value of deferred and contingent consideration2,400(11,700)
Total operating expenses337,997235,257
Loss from operations(117,615)(86,522)
Interest expense, net(27,331)(23,514)
Other income (expense), net9,956(11,855)
Loss before income tax expense(134,990)(121,891)
Income tax expense(3,969)(4,835)
Net loss attributable to common stockholders$ (138,959)$ (126,726)
Weighted-average shares outstanding:  
Basic73,729,28471,215,105
Diluted73,729,28471,215,105
Net loss per share-basic and diluted (in dollars per share)  
Basic$ (1.88)$ (1.78)
Diluted$ (1.88)$ (1.78)
Net product revenue  
Revenues:  
Revenue$ 187,557$ 129,832
Collaboration revenue  
Revenues:  
Revenue67
Royalty revenue  
Revenues:  
Revenue30,83118,896
Manufacturing revenue  
Revenues:  
Revenue$ 1,988$ 0

PTCT Balance Sheet

2023-03-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 167,495$ 279,834
Marketable securities118,808130,871
Trade and royalty receivables, net201,867155,614
Inventory, net26,64921,808
Prepaid expenses and other current assets98,573105,658
Total current assets613,392693,785
Fixed assets, net79,49272,590
Intangible assets, net686,205705,891
Goodwill82,34182,341
Operating lease ROU assets99,531102,430
Deposits and other assets47,87848,582
Total assets1,608,8391,705,619
Current liabilities:  
Accounts payable and accrued expenses332,091320,366
Deferred revenue2141,351
Operating lease liabilities- current9,5989,370
Finance lease liabilities- current1,8573,000
Liability for sale of future royalties - current97,87472,149
Total current liabilities441,634406,236
Long-term debt572,091571,722
Contingent consideration payable166,400164,000
Deferred tax liability102,831102,834
Operating lease liabilities- noncurrent100,442100,860
Finance lease liabilities- noncurrent17,18418,675
Liability for sale of future royalties- noncurrent665,677685,737
Other long-term liabilities1412,641
Total liabilities2,066,4002,052,705
Stockholders' deficit:  
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 74,012,034 shares at March 31, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 20227372
Additional paid-in capital2,339,8862,305,020
Accumulated other comprehensive (loss) income(1,587)4,796
Accumulated deficit(2,795,933)(2,656,974)
Total stockholders' deficit(457,561)(347,086)
Total liabilities and stockholders' deficit$ 1,608,839$ 1,705,619